Eli Lilly and Merck Present Combined Therapy Data for Lung Cancer
What happened
Eli Lilly and Company presented new first-line data on olomorasib, its investigational KRAS G12C inhibitor, at the 2026 European Society for Medical Oncology Congress. The results, shared from the Phase 1/2 LOXO-RAS-20001 trial and the safety lead-in of SUNRAY-01, showed durable activity when olomorasib was combined with Merck's anti-PD-1 therapy, KEYTRUDA®, in advanced KRAS G12C-mutant non-small cell lung cancer. Median progression-free survival and duration of response had not been reached after nearly 21 months of follow-up. Eli Lilly expects first randomized Phase 3 data from SUNRAY-01 in the first half of 2027.
From prnewswire.com
Why it matters
The presentation highlights the efficacy of combining olomorasib with KEYTRUDA® in treating a difficult-to-treat form of lung cancer. This clinical validation strengthens the oncology portfolio for Merck and addresses an unmet need in first-line treatment options for patients with KRAS G12C-mutant NSCLC.
AbbVie, Eli Lilly and Company, and Merck are broadening their therapeutic reach.
From prnewswire.com
Who's involved
- Eli Lilly and CompanyPresented the clinical trial data on olomorasib.
- MerckProvided the anti-PD-1 therapy, KEYTRUDA®, used in the combination trial.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- MerckSpeculative
Merck might see increased demand for its KEYTRUDA® therapy in the KRAS G12C-mutant non-small cell lung cancer market.
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Merck
public company in Indonesia
Related events
- Foghorn's FHD-909 trial advances with Eli Lilly and Company.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
- Eli Lilly and Company collaborated with Adlai Nortye Ltd. for a clinical trial supply agreement.
- Moderna and Merck developed a new therapy.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.